AKL Research and Development
Executive Team
David Miles: CEO
Commercial executive, previously Head of Inflammatory diseases, Europe at Pfizer. UK, EMEA and Global experience in emerging and established, biotech and pharmaceutical sectors, including pre-IPO. Demonstrable track record of building and leading commercial, access and medical teams to create and execute portfolio strategy.
Alan Reynolds: CSO
Clinical Scientist with wide ranging experience across a number of therapeutic areas. Previously European Clinical Science Director Inflammation for Wyeth/Pfizer responsible for providing European input into global research and publication strategies and leading health economic submissions to NICE.
Dr. Nicholas Larkins BVSc DSc MRCVS: CRO
Clinician with extensive research interests in pharmacognosy specifically focused on immunomodulatory phyto-pharmaceuticals and the roles they play in inflammation and the resolution of inflammation.
Michael Martin FCCA: CFO
Partner in Anvil Partners LLP since 1995, advising companies on private equity transactions and mergers & acquisitions. Previously 18 years in investment banking in London, New York, and Paris with Kleinwort Benson and qualified as a chartered accountant with Price Waterhouse.
Wendy Richings Barrow: Regulatory
35 years experience in the pharma industry. Former Regulatory Affairs Manager, Lederle Laboratories before becoming Licensing & Acquisition Manager, Lederle Laboratories. Currently GM Subiaco Associates Ltd, Healthcare Regulatory Consultancy.
David Sharples: Chair
Serial entrepreneur, experienced in recruiting and supervising strong management teams. Extensive senior management roles including successful fund-raising, commercial deals and company trade sales.